Ubs Group Ag Adc Therapeutics Sa Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Ubs Group Ag holds 767,064 shares of ADCT stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

767,064

Previous 884,518 13.28%

Holding current value

$2.05 Million

Previous $1.76 Million 38.58%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$1.39 - $2.02 $163,261 - $237,257	-117,454 Reduced 13.28%	767,064 $1.08 Million
Q4 2024 Feb 14, 2025	BUY	$1.89 - $3.48 $1.6 Million - $2.94 Million	844,743 Added 2123.8%	884,518 $1.76 Million
Q3 2024 Nov 14, 2024	BUY	$2.59 - $4.01 $48,127 - $74,513	18,582 Added 87.68%	39,775 $125,000
Q2 2024 Aug 13, 2024	BUY	$2.55 - $5.09 $53,912 - $107,612	21,142 Added 41454.9%	21,193 $66,000
Q1 2024 May 13, 2024	BUY	$1.66 - $5.29 $84 - $269	51 New	51 $0
Q1 2023 May 12, 2023	BUY	$1.92 - $5.45 $16,101 - $45,703	8,386 Added 287.59%	11,302 $22,000
Q4 2022 Feb 08, 2023	BUY	$2.87 - $5.24 $8,368 - $15,279	2,916 New	2,916 $11,000
Q1 2022 May 16, 2022	SELL	$13.28 - $20.03 $32,217 - $48,592	-2,426 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$19.29 - $31.51 $46,797 - $76,443	2,426 New	2,426 $49,000
Q3 2021 Nov 15, 2021	SELL	$20.45 - $30.0 $3,210 - $4,710	-157 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$22.75 - $34.05 $29,757 - $44,537	-1,308 Reduced 89.28%	157 $4,000
Q4 2020 Feb 11, 2021	BUY	$25.26 - $38.02 $33,444 - $50,338	1,324 Added 939.01%	1,465 $47,000
Q3 2020 Nov 12, 2020	BUY	$32.87 - $51.05 $4,634 - $7,198	141 New	141 $5,000

Others Institutions Holding ADCT

# of Institutions

Shares Held

53.9M

Call Options Held

Put Options Held

7.6K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $207M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account